Study guide

2.2 Anemia of Chronic Inflammation, Sideroblastic Anemias & Lead Toxicity

ASCP Hematology Technologist Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Hematopoiesis & Cellular Physiology

1.1 Hematopoiesis, Bone Marrow Microenvironment & Growth Factors 1.2 Erythrocyte Physiology, Metabolism & Destruction Pathways 1.3 Leukocyte Kinetics, Morphology & Phagocytic Function 1.4 Platelet Physiology, Ultrastructure & Thrombopoiesis

2 Chapter 2: Erythrocyte Disorders & Non-Hemolytic Anemias

2.1 Iron Metabolism & Iron Deficiency Anemia 2.2 Anemia of Chronic Inflammation, Sideroblastic Anemias & Lead Toxicity 2.3 Hemoglobinopathies & Qualitative Globin Chain Defects 2.4 Alpha and Beta Thalassemias 2.5 Megaloblastic, Macrocytic & Hypoproliferative Anemias

3 Chapter 3: Hemolytic Anemias & Erythrocytosis

3.1 Intrinsic Hemolytic Anemias: Membrane & Metabolic Defects 3.2 Immune-Mediated Hemolytic Anemias & Paroxysmal Nocturnal Hemoglobinuria 3.3 Non-Immune Extrinsic Hemolytic Anemias & Microangiopathies 3.4 Polycythemia & Erythrocytosis Classification

4 Chapter 4: Benign Leukocyte Alterations, Acute Leukemias & Bone Marrow Evaluation

4.1 Quantitative Leukocyte Alterations, Toxic Change & Leukemoid Reaction 4.2 Inherited Leukocyte Anomalies, Reactive Lymphocytosis & Storage Disorders 4.3 Acute Myeloid Leukemia (AML) & Related Neoplasms 4.4 Acute Lymphoblastic Leukemia (ALL) & Precursor Lymphoid Neoplasms 4.5 Bone Marrow Examination, Differential & M:E Ratio Assessment

5 Chapter 5: Chronic Myeloid Neoplasms, MDS & Mature Lymphoid Neoplasms

5.1 Myelodysplastic Syndromes (MDS) & Overlap Syndromes 5.2 Chronic Myeloproliferative Neoplasms (CML, PV, ET, PMF) 5.3 Chronic Lymphocytic Leukemia & Indolent B-Cell Lymphomas 5.4 Aggressive Lymphomas, Hodgkin Lymphoma & Mature T-Cell Disorders 5.5 Plasma Cell Neoplasms & Monoclonal Gammopathies

6 Chapter 6: Hemostasis: Primary, Secondary & Fibrinolytic Systems

6.1 Primary Hemostasis, Platelet Receptors & Qualitative Platelet Disorders 6.2 Quantitative Platelet Disorders & Immune Thrombocytopenias 6.3 The Coagulation Cascade & Cell-Based Hemostatic Model 6.4 Fibrinolytic System, Natural Anticoagulants & Thrombophilia

7 Chapter 7: Factor Deficiencies, Coagulation Testing & Anticoagulation

7.1 Hereditary Coagulation Factor Deficiencies & von Willebrand Disease 7.2 Acquired Coagulation Factor Deficiencies, Circulating Inhibitors & DIC 7.3 Routine and Specialized Coagulation Testing & Mixing Study Interpretation 7.4 Anticoagulant Therapies, Laboratory Monitoring & Reversal Strategies 7.5 Viscoelastic Testing, Heparin Neutralization & Chromogenic Assays

8 Chapter 8: Hematology Laboratory Testing & Advanced Diagnostics

8.1 Automated Hematology Analyzers, Interference Flags & Manual Methods 8.2 Cytochemical Staining, Flow Cytometry & Molecular Diagnostics 8.3 Erythrocyte Sedimentation Rate, Hemolytic Indicators & Special Erythrocyte Studies 8.4 Cerebrospinal Fluid Analysis, Cell Counts & Cytology 8.5 Serous Effusions & Synovial Fluid Analysis

9 Chapter 9: Laboratory Operations, Quality Assessment & Safety

9.1 The Total Testing Process: Preanalytical, Analytical & Postanalytical Quality 9.2 Quality Control Statistics, Levey-Jennings Charts & Westgard Multirules 9.3 Laboratory Mathematics: Dilutions, Concentration, Molarity & Standard Curves 9.4 Method Evaluation, Diagnostic Statistics & Point-of-Care Testing 9.5 Regulatory Framework, Proficiency Testing & Competency Assessment 9.6 Laboratory Safety: Bloodborne Pathogens, Personal Protective Equipment & Chemical Hygiene 9.7 Emergency Response, Spill Management & Specimen Packaging and Transport 9.8 Hematology Instrumentation: Microscopy, Counters, Analyzers & Centrifuges

2.2 Anemia of Chronic Inflammation, Sideroblastic Anemias & Lead Toxicity

Key Takeaways Explain This Topic AI

Anemia of chronic inflammation is driven by interleukin-6 induced hepcidin: iron is trapped in macrophages, so serum iron is low, total iron-binding capacity is LOW (unlike iron deficiency, where it is high), ferritin is normal to high, and marrow storage iron is normal to increased.

The soluble transferrin receptor is low to normal in anemia of chronic inflammation and high in iron deficiency, making the soluble transferrin receptor / log ferritin index the standard tiebreaker when both conditions coexist.

A ring sideroblast is an erythroid precursor with at least five siderotic granules encircling at least one third of the nucleus, demonstrated only by the Prussian blue (Perls acid ferrocyanide) reaction.

Sideroblastic anemias show HIGH serum iron, high transferrin saturation, and high ferritin with a dimorphic blood picture; hereditary forms are typically ALAS2-related and pyridoxine responsive, while acquired forms include MDS with ring sideroblasts and alcohol, isoniazid, chloramphenicol, linezolid, zinc, and lead exposures.

Lead inhibits delta-aminolevulinic acid dehydratase and ferrochelatase in the heme pathway and inhibits pyrimidine-5'-nucleotidase, producing coarse basophilic stippling with raised free erythrocyte protoporphyrin and zinc protoporphyrin.

Last updated: August 2026

Anemia of Chronic Inflammation, Sideroblastic Anemias & Lead Toxicity

Not every microcytic or hypochromic anemia is caused by a lack of iron. Three disorders reproduce parts of the iron deficiency picture while requiring completely different management: anemia of chronic inflammation, in which iron is abundant but sequestered; the sideroblastic anemias, in which iron reaches the mitochondrion but cannot be inserted into protoporphyrin IX; and lead toxicity, in which two heme-pathway enzymes and a nucleotide-degrading enzyme are poisoned simultaneously. The ASCP BOC tests these as a differential set, so learn the iron studies and the marrow iron stain findings side by side.

Anemia of Chronic Disease / Chronic Inflammation (ACD/ACI)

Anemia of Chronic Disease (also termed Anemia of Chronic Inflammation) is the second most prevalent anemia worldwide and the most common anemia among hospitalized patients. It accompanies chronic systemic infections (tuberculosis, osteomyelitis, HIV, subacute bacterial endocarditis), autoimmune and rheumatologic disorders (rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease), and solid or hematologic malignancies.

Pathophysiological Mechanisms

Hepcidin Hypersecretion : Macrophages and T-cells release inflammatory cytokines ( IL-6, TNF- α \alpha α , IL-1, IFN- γ \gamma γ ). IL-6 directly stimulates hepatocyte transcription of hepcidin via the STAT3 pathway. High hepcidin levels degrade ferroportin, trapping iron in the macrophage storage compartment.

Impaired Iron Mobilization & Hypoferremia : Despite rich total-body iron stores, iron cannot be released to apotransferrin. Erythroid progenitors become iron-starved amidst abundant storage iron ("iron entrapment syndrome").

Blunted Erythropoietin Response : TNF- α \alpha α and IFN- γ \gamma γ directly suppress renal peritubular EPO gene expression, blunting the expected compensatory EPO surge. Furthermore, these cytokines release reactive oxygen species that induce direct apoptosis of CFU-E and BFU-E erythroid colonies.

Shortened Erythrocyte Lifespan : Non-specific hyperactivation of reticuloendothelial macrophages accelerates premature destruction of normal circulating red blood cells (shortening lifespan by 20–30%).

Laboratory Hallmarks & Differentiation from IDA

Serum Iron : Decreased (typically 20 to 50 μ g/dL 20\text{ to }50\text{ }\mu\text{g/dL} 20 to 50 μ g/dL ).

TIBC : Normal to Decreased ( 100 to 250 μ g/dL 100\text{ to }250\text{ }\mu\text{g/dL} 100 to 250 μ g/dL ) because transferrin is a negative acute-phase reactant whose hepatic synthesis is downregulated during systemic inflammation.

Transferrin Saturation : Low to normal (typically 10 % to 20 % 10\%\text{ to }20\% 10% to 20% ).

Serum Ferritin : Normal to Significantly Elevated ( 100 to 1000 + ng/mL 100\text{ to }1000+\text{ ng/mL} 100 to 1000 + ng/mL ) because ferritin is a positive acute-phase reactant upregulated by cytokines.

Soluble Transferrin Receptor (sTfR) : Normal in uncomplicated ACD (erythroblasts do not upregulate TfR1 because inflammation suppresses erythropoiesis), whereas sTfR is significantly elevated in IDA . The sTfR / log ⁡ 10 \log_{10} lo g 10 ​ Ferritin Index ( < 1.0 <1.0 < 1.0 in ACD; > 2.0 >2.0 > 2.0 in IDA or combined IDA/ACD) is an essential diagnostic discriminator.

Bone Marrow Findings : Prussian blue staining reveals abundant coarse hemosiderin aggregates inside marrow macrophages , but an absence or severe depletion of iron granules within developing normoblasts (sideroblasts < 10 % <10\% < 10% , normal is 30 % to 50 % 30\%\text{ to }50\% 30% to 50% ).

Sideroblastic Anemias

Sideroblastic anemias represent a heterogeneous group of disorders characterized by defective mitochondrial protoporphyrin and heme synthesis. Because iron enters developing erythroblasts normally via transferrin endocytosis but cannot be incorporated into the protoporphyrin IX ring, excess iron accumulates inside the inner mitochondrial matrix. Normal Erythroblast Mitochondria: Sideroblastic Anemia Mitochondria:

  • Protoporphyrin IX + Fe²⁺ ──► Heme Defective Porphyrin Synthesis ──► Fe²⁺ Accumulation
  • (Iron utilized & dispersed) (Iron aggregates in perinuclear mitochondria)
  • ═════════════════════════════════════════════════
  • Prussian Blue: Ring Sideroblast (≥5 iron granules
  • encircling ≥1/3 of the nuclear circumference)
  • Hereditary vs. Acquired Etiologies

Hereditary Sideroblastic Anemia :

X-linked Sideroblastic Anemia (XLSA) : The most common inherited form, caused by loss-of-function mutations in the A L A S 2 ALAS2 A L A S 2 gene (Xp11.21), which encodes erythroid-specific 5-aminolevulinate synthase. A L A S 2 ALAS2 A L A S 2 catalyzes the initial and rate-limiting step of heme synthesis (condensation of glycine and succinyl-CoA to form δ \delta δ -aminolevulinic acid) and requires pyridoxal 5'-phosphate (vitamin B 6 B_6 B 6 ​ ) as a cofactor. Patients often demonstrate partial responsiveness to high-dose pyridoxine therapy.

Autosomal recessive forms involve mutations in mitochondrial transporter genes such as SLC25A38 or mitochondrial iron-sulfur cluster assembly machinery ( ABCB7 , GLRX5 ).

Acquired Sideroblastic Anemia :

Clonal / Neoplastic (MDS-RS) : Myelodysplastic Syndrome with Ring Sideroblasts, strongly associated with somatic mutations in the S F 3 B 1 SF3B1 SF 3 B 1 gene (splicing factor 3b subunit 1) or other RNA spliceosome machinery, leading to mitochondrial iron handling failure.

Reversible / Toxic-Metabolic :

Chronic Alcohol Abuse : Ethanol acts as a direct mitochondrial toxin that suppresses A L A S 2 ALAS2 A L A S 2 , ferrochelatase, and pyridoxal kinase activity.

Medications : Isoniazid (INH) , an anti-tubercular agent that antagonizes pyridoxal phosphate; chloramphenicol and linezolid, which inhibit mitochondrial ribosome translation.

Copper Deficiency / Zinc Toxicity : Copper is required for ceruloplasmin/hephaestin and cytochrome c oxidase; excess zinc ingestion (e.g., denture creams) upregulates enterocyte metallothionein, which traps copper and prevents its absorption.

The Ring Sideroblast & Prussian Blue Iron Stain

A ring sideroblast is an abnormal erythroid precursor (normoblast) identified on bone marrow aspirate smears stained with Prussian blue (Perls' acid ferrocyanide) . The diagnostic criteria require 5 or more siderotic iron granules encircling at least one-third ( ≥ 1 / 3 \ge 1/3 ≥ 1/3 ) of the nuclear circumference . These granules correspond ultrastructurally to iron-overloaded, swollen mitochondria hugging the outer nuclear envelope.

Peripheral Smear & Laboratory Profile

Dimorphic RBC Population : A hallmark feature visible on peripheral blood smears and reflected in a markedly elevated RDW. The smear exhibits two distinct erythrocyte populations: microcytic hypochromic cells (from defective clones) and normocytic normochromic cells (or macrocytes in MDS).

Pappenheimer Bodies (Siderotic Granules) : Distinct, small, dense, dark-purple irregular inclusions located at the cell periphery on Wright-Giemsa stain. Composed of iron aggregates complexed with protein, they turn vivid blue-green when confirmed with Prussian blue stain.

Iron Studies Profile : Demonstrates marked systemic iron overload due to ineffective erythropoiesis suppressing hepcidin: markedly elevated serum iron, normal to low TIBC, high transferrin saturation (>50–80%), and markedly elevated serum ferritin (>500–1500 ng/mL) .

Lead Poisoning (Plumbism)

Lead is a potent environmental heavy metal toxin that causes multi-organ pathology, encephalopathy, abdominal colic, peripheral motor neuropathy (wrist drop/foot drop), and a characteristic microcytic or normocytic anemia.

Molecular Enzymatic Disruptions

Inhibition of δ \delta δ -Aminolevulinic Acid Dehydratase ( δ \delta δ -ALAD / Porphobilinogen Synthase) : Lead displaces essential zinc ions from δ \delta δ -ALAD, blocking the condensation of two δ \delta δ -ALA molecules into porphobilinogen (PBG). This leads to marked accumulation and urinary excretion of δ \delta δ -aminolevulinic acid (ALA) .

Inhibition of Ferrochelatase (Heme Synthase) : Lead directly poisons the mitochondrial enzyme ferrochelatase, preventing the final insertion of ferrous iron ( F e 2 + Fe^{2+} F e 2 + ) into protoporphyrin IX. Unchelated protoporphyrin IX combines non-enzymatically with zinc to form Zinc Protoporphyrin (ZPP) , which fluoresces under ultraviolet light.

Inhibition of Pyrimidine 5'-Nucleotidase : Lead inhibits pyrimidine 5'-nucleotidase, the enzyme responsible for clearing digested ribosomal ribonucleic acid (rRNA) during reticulocyte maturation. Undegraded rRNA aggregates into visible cytoplasmic precipitates. Heme Biosynthesis Pathway Disruptions in Lead Toxicity

  • Succinyl-CoA + Glycine
  • │
  • │ (ALAS2 - Requires Pyridoxal 5'-Phosphate / Vit B6)
  • ▼
  • δ-ALA (delta-Aminolevulinic Acid)
  • │
  • ├───────────────────────────► [BLOCKED BY LEAD] ──► ↑ Urinary δ-ALA
  • │ (δ-ALAD / Zinc-Dependent)
  • ▼
  • Porphobilinogen (PBG)
  • │

▼ ...

  • Protoporphyrin IX + Fe²⁺
  • │
  • ├───────────────────────────► [BLOCKED BY LEAD] ──► ↑ Free Erythrocyte Protoporphyrin (FEP)
  • │ (Ferrochelatase) ↑ Zinc Protoporphyrin (ZPP)
  • ▼
  • HEME
  • Hematologic Morphology & Diagnostic Testing

Coarse Basophilic Stippling : The diagnostic morphologic hallmark on Wright-Giemsa stained peripheral blood smears. Appears as numerous coarse, punctate, deep-blue granules distributed evenly throughout the entire erythrocyte cytoplasm, representing precipitated ribosomal RNA aggregates.

Whole Blood Lead Level (BLL) : The definitive gold-standard confirmatory test (diagnostic threshold in children ≥ 3.5 μ g/dL \ge 3.5\text{ }\mu\text{g/dL} ≥ 3.5 μ g/dL per CDC guidelines; toxic manifestations typically appear > 20 to 45 μ g/dL >20\text{ to }45\text{ }\mu\text{g/dL} > 20 to 45 μ g/dL ).

Erythrocyte Protoporphyrin (FEP / ZPP) : Markedly elevated, serving as a durable indicator of prolonged cellular toxicity.

Comparative Differential Diagnosis of Microcytic Hypochromic Anemias

The following clinical laboratory matrix summarizes the critical biochemical and morphologic parameters required to distinguish microcytic hypochromic disorders on the ASCP BOC examination:

Laboratory / Morphologic Parameter Iron Deficiency Anemia (IDA) Anemia of Chronic Disease (ACD) Sideroblastic Anemia (SA) β \beta β -Thalassemia Minor / Trait Lead Poisoning (Plumbism)

Serum Iron Markedly Decreased ( < 30 μ g/dL <30\text{ }\mu\text{g/dL} < 30 μ g/dL ) Decreased ( 20 − 50 μ g/dL 20-50\text{ }\mu\text{g/dL} 20 − 50 μ g/dL ) Markedly Elevated ( > 160 μ g/dL >160\text{ }\mu\text{g/dL} > 160 μ g/dL ) Normal to Elevated Normal to Slightly Decreased

TIBC Elevated ( > 450 μ g/dL >450\text{ }\mu\text{g/dL} > 450 μ g/dL ) Decreased to Normal ( 100 − 250 μ g/dL 100-250\text{ }\mu\text{g/dL} 100 − 250 μ g/dL ) Normal to Decreased Normal ( 250 − 400 μ g/dL 250-400\text{ }\mu\text{g/dL} 250 − 400 μ g/dL ) Normal

Transferrin Saturation Markedly Decreased ( < 10 − 15 % <10-15\% < 10 − 15% ) Normal to Decreased ( 10 − 20 % 10-20\% 10 − 20% ) Markedly Elevated ( > 50 − 80 % >50-80\% > 50 − 80% ) Normal to Elevated ( 25 − 50 % 25-50\% 25 − 50% ) Normal to Slightly Decreased

Serum Ferritin Critically Low ( < 12 − 15 ng/mL <12-15\text{ ng/mL} < 12 − 15 ng/mL ) Normal to Elevated ( 100 − 1000 + ng/mL 100-1000+\text{ ng/mL} 100 − 1000 + ng/mL ) Markedly Elevated ( > 500 − 1500 ng/mL >500-1500\text{ ng/mL} > 500 − 1500 ng/mL ) Normal to Elevated ( 50 − 300 ng/mL 50-300\text{ ng/mL} 50 − 300 ng/mL ) Normal to Elevated

  • Soluble TfR (sTfR) Markedly Elevated Normal Normal to Decreased Normal to Elevated Normal
  • FEP / ZPP Markedly Elevated Normal to Moderately Elevated Normal to Elevated Normal Markedly Elevated

Marrow Macrophage Iron Absent (0) Abundant / Increased (3+ to 4+) Abundant / Increased Normal to Increased Normal to Increased

Ring Sideroblasts Absent Absent Present ( ≥ 15 % \ge 15\% ≥ 15% of precursors) Absent Occasional / Absent

RDW Markedly Elevated ( > 15 − 20 % >15-20\% > 15 − 20% ) Normal to Slightly Elevated ( 12 − 15 % 12-15\% 12 − 15% ) Markedly Elevated (Dimorphic) Strictly Normal ( 11.5 − 14.0 % 11.5-14.0\% 11.5 − 14.0% ) Elevated ( 14 − 18 % 14-18\% 14 − 18% )

RBC Count Decreased ( < 3.5 × 10 12 /L <3.5\times 10^{12}\text{/L} < 3.5 × 1 0 12 /L ) Decreased to Low Normal Decreased to Normal Markedly Elevated ( > 5.0 − 6.5 × 10 12 /L >5.0-6.5\times 10^{12}\text{/L} > 5.0 − 6.5 × 1 0 12 /L ) Normal to Decreased

Key Smear Morphology Microcytes, pencil/cigar cells, severe pallor Microcytes or normocytes, minimal poikilocytosis Dimorphic RBCs, Pappenheimer bodies, stippling Striking microcytosis, abundant codocytes, basophilic stippling Coarse basophilic stippling, mild microcytosis